Find Academic Supervisors

Simon KolstoeView profile

Associate Professor

• Research Ethics
• Research Integrity
• Research Governance
• +4 more

Dr. Simon Kolstoe serves as Associate Professor in Bioethics and University Ethics Adviser at the University of Portsmouth within the Faculty of Humanities and Social Sciences and School of Area Studies, Sociology, History, Politics, and Literature. As a PhD Supervisor and active contributor to national ethics frameworks, he bridges academic research with practical governance across multiple UK government sectors. His educational background includes: PhD in Biochemistry, University of Southampton (2005) BA in Philosophy, Open University MA in Research Ethics, Keele University Kolstoe's research centers on Research Ethics and Integrity with specialized focus on medical and defence research involving human participants. His work critically examines ethics committee review quality, defence and dual use research governance, human challenge trial protocols, research waste reduction, and cultural transformation in research environments. He actively shapes national policy through collaborations with the NHS Health Research Authority, UK Health Security Agency, and Ministry of Defence. His 2024-2025 publications reveal evolving priorities across three interconnected domains: crisis decision-making in public health (evident in his public health authority model), standardization challenges in emerging research methodologies (particularly human challenge studies), and systemic integrity issues spanning vaccine research replication to AI integration in ethics review. These works consistently emphasize practical governance solutions while addressing ethical tensions in defence contexts and participant autonomy. As PhD Supervisor, Kolstoe leverages his BBSRC New Investigators Award background to mentor next-generation researchers. His current funding stems from institutional roles within major UK government ethics frameworks rather than traditional grants. He directs critical national infrastructure including: Ministry of Defence Research Ethics Committee (MODREC) Chair UK Health Security Agency Research Ethics and Governance Group (REGG) Chair Health Research Authority Community Committee Member UK Research Integrity Office (UKRIO) Trustee His operational teams drive initiatives like "Think Ethics," "Make it Public," and the fast-track REC pilot, positioning him at the nexus of academic bioethics and national research policy implementation.

• Bayesian Modeling
• Longitudinal Data Analysis
• Experimental Designs
• +5 more

Elizabeth Slate is a Professor in the Department of Statistics at Florida State University. Her expertise includes longitudinal data analysis, experimental designs, and Bayesian modeling. She focuses on interdisciplinary applications in biomedical research, particularly in musculoskeletal biomechanics, clinical trial design, and public health disparities. Her work bridges statistical methodology with real-world clinical and epidemiological challenges. Research Interests: Her research spans Bayesian statistical methods, causal inference, and the analysis of complex biomedical datasets. Key areas include biomechanical modeling of joint disorders, risk factor analysis for chronic diseases, and the development of innovative statistical frameworks for clinical trials and observational studies. She has contributed to understanding the structural-functional relationships in musculoskeletal tissues and the sociocultural determinants of health behaviors in underserved populations. Publications Trends: Recent work emphasizes Bayesian borrowing of historical data in basket trials, explainable AI in medical imaging, and the biomechanical correlates of TMJ disorders. She also investigates longitudinal health outcomes in diabetes and HPV vaccination uptake among marginalized groups. Methodologically, her articles address causal mediation, sensitivity analysis, and mixed-scale data integration. Grants and Advising: While specific grant details are not listed, her publication record indicates sustained funding in interdisciplinary health research. No advising information is explicitly provided in the source text. Labs/Teams: Collaboration networks likely span biomedical engineering, public health, and clinical departments, though formal affiliations are not detailed here.

Cindy J NowinskiView profile

Research Professor

• Health Services Research
• Clinical Research
• Healthcare Quality
• +7 more

Cindy J Nowinski, MD, PhD is a Research Professor in the Departments of Medical Social Sciences (Outcome and Measurement Science, Determinants of Health, Implementation Science) and Neurology (Ken and Ruth Davee Department) at Northwestern University Feinberg School of Medicine. She is affiliated with the Institute for Public Health and Medicine (IPHAM) - Center for Patient-Centered Outcomes and the Northwestern University Clinical and Translational Sciences Institute (NUCATS). Dr. Nowinski earned her BS (1982), MA (1986), and PhD (1991) from Loyola University of Chicago, followed by an MD (2000) from Northwestern University Feinberg School of Medicine. Trained as both a clinical psychologist and physician, she brings a unique interdisciplinary perspective to her research. With over 20 years of experience, Dr. Nowinski is a leading expert in developing patient-reported outcome measures and performance-based cognitive assessments for children and adults. Her research focuses on improving health and healthcare quality through standardized outcome measures, with particular emphasis on cognitive aging, neurological conditions (dementia, multiple sclerosis), and digital assessment technologies. She has played central roles in major national initiatives including Neuro-QoL, PROMIS, NIH Toolbox, Mobile Toolbox, and MyCog. Her recent publications reveal a strong emphasis on smartphone-based cognitive screening tools for primary care implementation, machine learning optimization of assessment algorithms, and validation of remote cognitive testing methods. This work demonstrates her commitment to translating research into practical clinical tools that improve early detection of cognitive impairment. Dr. Nowinski has received the Innovations Award from NorthShore University HealthSystem (2007) and holds numerous leadership positions including: Member, Digital Measures: Alzheimer's Disease and Related Dementias Working Group, Digital Medicine Society (2022-Present) Member, Clinical Practice Special Interest Group Working Group on PROMs as Screening Tools, International Society for Quality of Life Research (2020-Present) Associate Editor, Quality of Life Research (2018-2021) Guest Editor, Frontiers in Pediatrics (2019-2022) She maintains active involvement in multiple professional societies including PROMIS Health Organization, Alzheimer's Association ISTAART, Digital Medicine Society, and International Society for Quality of Life Research. Her research is conducted through collaborations focused on implementing digital cognitive assessment tools like MyCog and Mobile Toolbox in diverse clinical settings, with special attention to underserved communities.

Yvonne C LeeView profile

Professor

• Rheumatoid Arthritis
• Pain Mechanisms
• Central Sensitization
• +5 more

Yvonne C Lee, MD, MMSc is the Helen Myers McLoraine Professor of Rheumatology in the Department of Medicine at Northwestern University Feinberg School of Medicine. She holds multiple institutional affiliations including the Center for Circadian and Sleep Medicine, Center for Human Immunobiology, Institute for Public Health and Medicine (IPHAM), and Northwestern University Clinical and Translational Sciences Institute (NUCATS). Her clinical practice is based at Northwestern Memorial Hospital and Shirley Ryan AbilityLab. Dr. Lee's research focuses on understanding pain mechanisms in rheumatoid arthritis and other systemic rheumatic conditions, with emphasis on pain centralization and non-inflammatory pain pathways. Her work integrates clinical trials, quantitative sensory testing, neuroimaging, and patient-reported outcomes to develop effective pain management strategies. She leads multiple active clinical trials including CPIRA-2, IMPACT-Pain-RA, PROMOTER, and CATCH-US investigating pain centralization biomarkers and treatment responses in rheumatoid arthritis. Analysis of Dr. Lee's recent publications reveals a consistent research trajectory centered on pain centralization in rheumatic diseases, particularly examining the relationship between sleep disturbance, quantitative sensory testing abnormalities, and patient-reported pain outcomes. Her work increasingly incorporates multi-modal pain assessment and biomarker discovery to address unmet needs in chronic pain management for rheumatoid arthritis patients. Department of Medicine Teaching Award, Northwestern University Feinberg School of Medicine (2020) Department of Medicine Teaching Award, Northwestern University Feinberg School of Medicine (2019) Innovation Discovery, Partners Healthcare (2016) Chair's Research Award, Brigham & Women's Hospital (2014) Dr. Lee serves as Associate Editor for Arthritis and Rheumatology and has held editorial positions at Arthritis Care & Research and Pain Medicine. She leads multiple NIH-funded clinical trials with significant grant support, focusing on pain mechanisms in rheumatoid arthritis. Her mentorship extends through her role in the American College of Rheumatology Research and Publications Subcommittee and Early Career Investigator Subcommittee. Dr. Lee directs research initiatives within the Center for Circadian and Sleep Medicine and Center for Human Immunobiology, collaborating with interdisciplinary teams to investigate the intersection of immune dysregulation, sleep disturbances, and pain processing in rheumatic diseases. Her laboratory work integrates clinical phenotyping with quantitative sensory testing and neuroimaging to characterize pain pathways.

• Multiple Myeloma
• Hematology
• Stem Cell Transplantation
• +4 more

Professor Graham Jackson is a distinguished Professor of Haematology at Newcastle University's Faculty of Medical Sciences, where he has established himself as a leading researcher in multiple myeloma and hematological malignancies. His work primarily focuses on genetic profiling, clinical trial design, and improving treatment outcomes for myeloma patients through large-scale studies including the landmark Myeloma XI trial. Professor Jackson's research interests center on multiple myeloma, with particular emphasis on genetic risk stratification , clinical trial design , and optimizing treatment protocols for both transplant-eligible and transplant-ineligible patients. His work has significantly contributed to understanding the role of cytogenetic abnormalities, minimal residual disease monitoring, and the development of risk prediction models such as the UK Myeloma Research Alliance Risk Profile (MRP). His research spans from basic science investigations into the molecular mechanisms of myeloma to large-scale clinical trials that directly impact patient care. Analysis of Professor Jackson's extensive publication record reveals a clear trend toward increasingly sophisticated genetic and molecular profiling of myeloma patients. His recent work demonstrates a shift toward personalized medicine approaches, incorporating genomic data to predict treatment response and optimize therapeutic strategies. He has been instrumental in major clinical trials including the Myeloma XI study, which has transformed treatment paradigms for multiple myeloma, particularly in areas like maintenance therapy, risk-adapted treatment, and management of high-risk disease. Professor Jackson has received significant research funding from organizations including the Medical Research Council, Cancer Research UK, Celgene, and Amgen. His work on the development and validation of the UK Myeloma Research Alliance Risk Profile (MRP) has provided clinicians with a valuable tool for predicting outcomes in transplant-ineligible myeloma patients. His contributions to understanding the impact of the COVID-19 pandemic on myeloma diagnosis and treatment have also been particularly timely and relevant. As a principal investigator on numerous clinical trials, Professor Jackson has mentored many researchers in the field of hematology. His collaborative approach is evident in the extensive list of co-authors across his publications, reflecting partnerships with leading institutions and researchers worldwide. His work continues to shape clinical practice guidelines and improve outcomes for patients with multiple myeloma.

Amy HarwoodView profile

Professor

• Clinical Exercise Physiology
• Peripheral Artery Disease
• Cardiovascular Rehabilitation
• +3 more

Dr Amy Harwood is a Reader in Clinical Exercise Physiology at Manchester Metropolitan University (MMU), affiliated with the Institute of Sport and Department of Sport and Exercise Science. She serves as Deputy Research Lead and Theme Lead for Health, Wellbeing, and Communities, and chairs the Clinical Exercise Physiology UK practitioner working group. Her research focuses on exercise interventions for clinical populations, particularly peripheral artery disease (PAD), emphasizing prehabilitation and rehabilitation. She holds grants from the National Institute for Health and Care Research (NIHR) and collaborates with NHS partners and industry leaders. Education: BSc (Hons) Sport and Exercise Science, University of Portsmouth (2010–2013) MSc Human and Applied Physiology, King’s College London (2013–2014) PhD Medical Sciences, Hull York Medical School (2014–2017) Research Interests: Dr. Harwood’s work bridges clinical and applied settings, with emphasis on: Exercise and therapeutic interventions (heat therapy, electrical stimulation) Cardiovascular physiology and chronic disease management Health inequalities and community-based rehabilitation NIHR-funded trials, including the reHabilitation for individuals with chrOnic limb threatening ischemia Post rEvascularisation (HOPE) trial Grants & Partnerships: British Heart Foundation-funded PhD studentships (e.g., evaluating heat therapy for PAD) National Institute for Health Research grants (e.g., MAXIMISE trial on exercise prescription) Collaborations with Greater Manchester Integrated Care Partnership and MCR Active Awards: Coventry University Exceptional Performance Award (2022) Teaching: Leads the MSc Clinical Exercise Physiology program and teaches modules like Exercise Testing and Interpretation. Supervises BSc projects and doctoral students across multiple universities. Labs & Teams: Active in MMU’s Institute of Sport, contributing to translational research and clinical partnerships.

Holly HartmanView profile

Assistant Professor

• Biostatistics
• Oncology
• Health Disparities
• +3 more

Holly Hartman, PhD, is an Assistant Professor in the Department of Population and Quantitative Health Sciences at Case Western Reserve University School of Medicine. Her research focuses on leveraging biostatistical methods to improve clinical trial design and analysis, particularly in oncology. She is a member of the Population and Cancer Prevention Program at the Case Comprehensive Cancer Center. Dr. Hartman holds a PhD in Biostatistics from the University of Michigan (2021), an MS in Biostatistics from the University of Alabama (2016), and a BS in Mathematics and Molecular & Cellular Biology from the University of Puget Sound (2011). Her work emphasizes addressing racial disparities in prostate cancer outcomes and optimizing radiation therapy approaches. Her research interests include clinical trial methodology, health disparities, and the integration of social determinants of health into oncology research. Recent studies have explored PSA screening policies, racial inequities in prostate cancer care, and the efficacy of androgen deprivation therapy in localized prostate cancer treatment. Dr. Hartman is affiliated with the Wolstein Research Building and Robbins Building facilities at Case Western Reserve University. She actively contributes to professional organizations including the American Statistical Association and the International Biometrics Society.

• Biostatistics
• Clinical Trials
• Survival Analysis
• +5 more

Rebecca A Betensky is the Chair of the Department of Biostatistics and a Professor of Biostatistics at New York University’s School of Global Public Health. Previously, she held leadership roles at Harvard T.H. Chan School of Public Health, including directing the Harvard Catalyst Biostatistics Program and the Massachusetts Alzheimer’s Disease Research Center. Her research focuses on survival analysis methodologies, clinical trial design, and biomarker evaluation, particularly in neurologic conditions like Alzheimer’s disease and multiple sclerosis. Education details are not explicitly provided in the text. Her work emphasizes censored/truncated data analysis, p-value interpretation, and translational research in neurology. She leads NIH-funded training programs in neurostatistics and has pioneered methods for evaluating biomarkers in aging populations. Dr. Betensky has contributed to high-impact studies on post-COVID-19 neurodegeneration, racial disparities in Alzheimer’s biomarkers, and the epidemiology of mental health outcomes. Her articles span clinical trial design, biomarker validation, and public health policy analysis, reflecting interdisciplinary collaboration across biostatistics, neurology, and epidemiology. She currently serves on the National Cancer Institute’s Board of Scientific Counselors and has been recognized with the Spiegelman Award and ASA/ISI Fellowships. Grants: Directed a 15-year NIH T32 training program in neurostatistics; led diversity initiatives in Harvard’s Biostatistics programs. Labs/Teams: Collaborates with the Alzheimer’s Imaging Consortium, Massachusetts General Hospital Neurology Core, and Dana-Farber Cancer Center.

Sarah NorthcottView profile

Senior Lecturer

• Stroke and Aphasia Rehabilitation
• Psychosocial Well-being
• Solution-Focused Brief Therapy
• +7 more

Sarah Northcott is a Senior Lecturer and Clinical Academic at the Division of Language and Communication Science within the School of Health Sciences at City St George's, University of London. She is also a Research Affiliate at the Centre for Research Excellence in Aphasia Recovery and Rehabilitation, La Trobe University, Australia, and was a part-time Senior Lecturer at the University of East Anglia from 2019 to 2021. Her educational background includes a PhD in 'Social support after a stroke' and an MSc in Speech and Language Therapy, both from City, University of London. She also holds a BA Hons in Music from the University of Cambridge and a PGDiploma in Piano Accompaniment from the Royal Academy of Music. Sarah’s research centers on enhancing the psychosocial well-being of individuals living with stroke and aphasia. She has two major research strands: (1) adapting Solution-Focused Brief Therapy (SFBT) for people with aphasia, notably through the SOFIA trial, and (2) exploring the lived experience of stroke and aphasia, including developing accessible outcome measures such as the Stroke Social Network Scale. Her recent projects include THEA, ELA, and the WISA project, all funded by major organizations including the Stroke Association and Sir Halley Stewart Trust. The 15 most recent articles reflect a consistent focus on psychosocial interventions, peer support, telehealth, and co-designed research methods. Key themes include emotional well-being, patient-centered care, intervention feasibility, and the role of healthcare staff in supporting recovery. The studies employ mixed methods, with strong emphasis on qualitative insights from people with aphasia and their families. 2016 Editor's Award, Journal of Speech Language and Hearing Research School of Health Sciences Postdoctoral Fellowship (2015) Stroke Association Jack and Averil (Mansfield) Bradley Fellowship (2016) Sarah has supervised multiple research projects and collaborated extensively with Dr. Katerina Hilari and other experts in aphasia rehabilitation. She has led funded grants totaling over £190,000 and is actively involved in public and patient engagement. She has contributed to editorial boards of journals such as Aphasiology and Clinical Rehabilitation , and serves on advisory committees including Aphasia United. Her work emphasizes co-production, ensuring that people with lived experience shape research priorities and outputs. She leads the WISA project (Wellbeing In Stroke and Aphasia), which began in 2023 and aims to develop an innovative, accessible psychological support service for people with aphasia. Her lab and research team operate within a participatory framework, integrating clinical practice, academic research, and community engagement to drive meaningful change in stroke rehabilitation services.

Dirk M. HermannView profile

Professor

• ATP-binding cassette transporters in the ischemic brain
• Diseases of the peripheral nervous system
• Clinical and Experimental Neuroimmunology
• +7 more

Prof. Dr. Dirk M. Hermann serves as a leading academic at the Clinic for Neurology within University Hospital Essen. His research focuses on vascular neurology, dementia research, and aging-related neurological disorders , with particular emphasis on ATP-binding cassette transporters, thromboinflammation, and restorative therapies for ischemic brain injury. Key research themes include neurovascular remodeling , neuronal-glial interactions , and secondary neurodegeneration following stroke. His recent publications highlight 2024 work on extracellular vesicles in brain plasticity , 2022 studies on post-stroke myeloid cell dynamics , and 2020 clinical trial design contributions in stroke recovery. His research integrates neuroimmunology with molecular cell biology to address stroke pathophysiology and recovery mechanisms. Collaborative projects span cardio-neurovascular interactions and nanoparticle neurodelivery systems , particularly evident in 2020 biomaterials research.

Christopher GoodchildView profile

Associate Professor

• Ecotoxicology
• Ecological Physiology
• Bioenergetics
• +3 more

Christopher Goodchild, Ph.D., serves as Associate Professor in the Biology Department at the University of Central Oklahoma, where he joined in 2020 following a postdoctoral position at Virginia Tech. His research integrates molecular physiology with whole-organism ecology to assess environmental contaminant impacts. His educational background: Ph.D. in Integrative Biology, Oklahoma State University (2019) M.S. in Marine Sciences, University of New England (2014) B.S. in Zoology and Biomedical Sciences, University of Oklahoma (2011) As an ecotoxicologist and ecological physiologist, Dr. Goodchild investigates links between molecular stress responses and fitness-related traits using interdisciplinary approaches spanning cellular physiology, bioenergetics, immunology, and behavior. His work primarily focuses on avian and aquatic systems exposed to contaminants like crude oil, triclosan, and lead, with emphasis on developing biomarkers for ecological hazard assessment. Analysis of his 2015-2020 publications reveals consistent investigation of contaminant effects across taxa, with strong emphasis on avian models (particularly zebra finches) and freshwater mussels. Key themes include biomarker development for oxidative stress, disruption of immune function by petroleum compounds, and behavioral-physiological trade-offs in energy allocation under environmental stress. Dr. Goodchild's scientific awards are not specified in the provided information. He maintains an active undergraduate mentoring program with demonstrable success: Jeff Krall: Accepted into University of Colorado Biochemistry PhD program Taryn Smith: Presented research at Society of Integrative and Comparative Biology conference K. Grisham & L.M. Schmidt: Published as undergraduate co-authors on multiple papers His mentees have transitioned successfully into molecular biology, veterinary medicine, and healthcare graduate programs. While specific grants aren't detailed, his active research program on contaminants suggests ongoing external funding. Dr. Goodchild leads the Ecotoxicology and Wildlife Physiology lab, which employs integrative methodologies to study how environmental stressors impact wildlife physiology and behavior across multiple biological scales.

• Information Security Behavior
• Technology Adoption
• Online Services
• +2 more

Professor Sigi Goode specializes in Information Systems at the ANU Research School of Management. His research examines information security behavior, technology adoption, and online service platforms. Current investigations focus on cybersecurity psychology, organizational fraud patterns, and social media's role in disaster response. His work has been funded by government agencies including the Department of Defence and AustCyber. Goode serves as associate editor for multiple information systems journals and has published in MIS Quarterly, Journal of Management Information Systems, and other leading publications.

• Hepatobiliary Surgery
• Pancreatic Surgery
• Oncological Surgery
• +5 more

Andrea Ruzzenente is a Full Professor of General Surgery and Hepatobiliary Surgery at the University of Verona. He serves as the Department Director of Chirurgia Generale ed Epatobiliare and coordinates the PhD Program in Surgical and Cardiovascular Sciences. His clinical and research activities focus on hepatobiliary and pancreatic surgery, with expertise in minimally invasive and robotic techniques for cancer treatment. Education and Roles: Department Director, Chirurgia Generale ed Epatobiliare PhD Coordinator, Surgical and Cardiovascular Sciences Member of multiple academic committees including the Faculty Board and Teaching Committees Research Interests: Clinical and molecular research in hepatobiliary cancers Development of minimally invasive surgical techniques Prognostic modeling in liver surgery Recent Articles: Focus on optimizing outcomes in liver surgery, robotic approaches, and predictive models for postoperative complications. Highlights include studies on hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. Teaching and Training: Lead instructor for advanced surgical courses (e.g., robotic surgery, minimally invasive techniques) Supervises postgraduate programs in General Surgery and Radiodiagnosis Labs and Teams: Associated with the Lurm Medical Research Laboratory and the Cardiovascular Research Laboratory. Involved in spin-off companies Nutretech S.r.l. and DiSS S.r.l. for translational research applications.

Adeyemi AdedejiView profile

Researcher

• Clinical Pathology
• Toxicology
• Translational Biomarkers
• +6 more

Adeyemi Adedeji serves as Distinguished Scientist-Pathologist and Head of Clinical Pathology in Translational Safety Pathology within Development Sciences at Genentech, where he has contributed for nine years to oncology and non-oncology therapeutic safety assessment. His expertise bridges clinical pathology, translational biomarker development, and immunotoxicology to support preclinical safety evaluation of biologics and small molecules. His educational background includes: Doctor of Veterinary Medicine (DVM) from University of Ibadan, Nigeria (2005) PhD in Molecular Microbiology from University of Missouri-Columbia (2012) Veterinary Clinical Pathology Residency at University of California-Davis (2015) Diplomate of American College of Veterinary Pathologists (2015) Dr. Adedeji's research focuses on advancing clinical pathology endpoints for drug safety assessment, with particular emphasis on urinary biomarker development, immunotoxicology, and implementation of 3Rs principles (Replacement, Reduction, Refinement) in toxicity studies. His work has established novel approaches for urinary biomarker normalization, microsampling techniques, and fasting protocol optimization to enhance animal welfare without compromising data quality. As Project Pathologist, he integrates clinical pathology data with anatomic findings to assess pharmacological and toxicological effects, directly contributing to regulatory submissions. His 33 Genentech publications demonstrate consistent focus on translational biomarker qualification, with recent work emphasizing deep learning applications in bone marrow analysis, bispecific antibody safety assessment, and cardiovascular toxicity mechanisms of TGFβ inhibitors. The research shows increasing sophistication in integrating multiple data streams for comprehensive safety assessment. His scientific recognition includes: 3Rs Genentech 1st place Award (2024) Society of Toxicology Best Paper Award (2023) 3Rs Global Roche 1st place award (2023) American College of Toxicology Best Paper Award (2020) Multiple Genentech Creative Genius Awards (2017-2018) As Project Pathologist, Dr. Adedeji provides scientific leadership across multiple therapeutic programs, collaborating with global pathologists and scientists to design preclinical safety studies and interpret findings for regulatory submissions. He actively contributes to establishing scientific standards through participation in the Scientific and Regulatory Policy Committee, focusing on integration of clinical and anatomic pathology data. His work with the 3Rs Advisory Group has led to significant refinements in toxicity study protocols, enhancing animal welfare while maintaining scientific rigor. Dr. Adedeji leads the Safety Biomarker Expert Resources team, driving scientific and technical support for identification, development, and validation of translational biomarkers. His group collaborates with global biomarker and immunotoxicology teams to advance technologies supporting safety studies and in-vivo safety models.

Henrik HolbechView profile

Associate Professor

• Ecotoxicology
• Endocrine Disruptors
• OECD Test Guidelines
• +2 more

Henrik Holbech is an Associate Professor in Ecotoxicology at the University of Southern Denmark 's Department of Biology. With over 124 research outputs, his work focuses on developing OECD test guidelines for identifying endocrine disrupting chemicals (EDCs) using fish and invertebrate models, particularly Danio rerio (zebrafish). He coordinates the EU Horizon 2020 ERGO project (€5.99M) and leads multiple Nordic Council-funded initiatives on mollusc endocrinology. As chair of the OECD Mollusc Expert Group and member of the ECHA Endocrine Disrupter Expert Group , he bridges human health and environmental toxicology through adverse outcome pathway (AOP) research. Research Contributions: Developed and validated Fish Sexual Development Test (FSDT) protocols (OECD TG 230/210/229) Pioneered mollusc-based EDC testing for aquatic invertebrates Lead author of OECD validation reports Contributor to 40+ international technical meetings Created ELISA methods for vitellogenin detection in fish Investigated ballast water treatment technologies (UV/cavitation/ozonation) Explored thyroid hormone disruption mechanisms in aquatic species Collaboration Network: Active in EU Tender projects with University of Heidelberg, University of Antwerp; Nordic Council partnerships (NordUTTE) with Norway/Sweden; Danish EPA collaborations (5.2 Mio DKK total). Key institutions: DHI Hoersholm, Fraunhofer, University of Antwerp.